Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1C | Q13936 | 2/20 | 0.43 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.43 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.43 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4110680 | 1.00 | CACNA1C (0.43) | CACNA1CCACNA1FCACNA1DCACNA1SMAPK1 | |
| SCHEMBL4110688 | 1.00 | CACNA1C (0.43) | CACNA1CCACNA1FCACNA1DCACNA1SMAPK1 | |
| SCHEMBL4113423 | 0.91 | CACNA1C (0.39) | CACNA1CCACNA1FCACNA1DCACNA1SMEN1 | |
| SCHEMBL4113427 | 0.91 | CACNA1C (0.39) | CACNA1CCACNA1FCACNA1DCACNA1SMEN1 | |
| SCHEMBL4113431 | 0.91 | CACNA1C (0.39) | CACNA1CCACNA1FCACNA1DCACNA1SMEN1 | |
| SCHEMBL13775882 | 0.91 | FDFT1 (0.39) | CACNA1CCACNA1FCACNA1DCACNA1S | |
| SCHEMBL13775856 | 0.87 | MEN1 (0.36) | CACNA1CCACNA1FCACNA1DCACNA1SMAPK1 | |
| SCHEMBL13743334 | 0.85 | DHFR (0.41) | MAPK1MEN1ALDH1A1MAPTPKM | |
| SCHEMBL13775877 | 0.85 | DHFR (0.41) | MAPK1MEN1ALDH1A1MAPTPKM | |
| SCHEMBL13775978 | 0.85 | CHRM1 (0.39) | MAPK1MEN1ALDH1A1MAPTPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090181942-A1 | TRICYCLIC COMPOUNDS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-07-16 | — | — | US | disclosed |
| EP-1939205-A1 | TRICYCLIC COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2008-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181942-A1 | TRICYCLIC COMPOUNDS | FDFT1, COASY, HMGCR | CACNA1C 2898/4885CACNA1F 3425/4885CACNA1D 2950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.